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• Observational studies indicate that even low intensity smoking increase mortality 
• We used Mendelian randomisation to investigate the causal associations between smoking 
intensity and all-cause and cause-specific mortality 
• Our study suggests that increased smoking intensity increases all-cause mortality, and 
mortality by respiratory disease and neoplasms 
• Our study finds weaker evidence of a causal effect of smoking intensity on death by 
circulatory disease. This is consistent with the effect of being a smoker compared to not 
being a smoker being stronger than the effect of higher compared to lower smoking intensity 






Background: Smoking is an important cause of mortality, and recent studies have suggested that 
even low intensity smoking might be associated with increased mortality. Still, smoking is associated 
with lower socioeconomic status as well as other potential risk factors, and disease onset might 
motivate smoking cessation, thus, residual confounding and reverse causality might bias results. We 
aimed to assess the evidence of a causal relationship between smoking intensity and cause-specific 
as well as all-cause-mortality using Mendelian randomisation analyses. 
Methods: We included 56,019 participants from the Norwegian HUNT2 Study and 337,103 
participants from the UK Biobank, linked to national registry data on causes of death. We estimated 
associations of self-reported smoking as well as the genetic variant rs1051730 as an instrument for 
smoking intensity with all-cause and cause-specific mortality. We subsequently meta-analysed the 
results from the two cohorts.  
Results: Each effect allele of the rs1051730 was associated with a 9% increased hazard of all-cause 
mortality (95% confidence interval 6-11%) among ever smokers. Effect alleles were also associated 
with death by neoplasms (HR 1.11, 95% CI 1.06-1.15), circulatory diseases (HR 1.06, 95% CI 1.01-
1.11), and respiratory diseases (HR 1.15, 95% CI 1.05-1.26) among ever smokers. The association was 
stronger among ever than never smokers for all-cause mortality (p <0.001), neoplasms (p=0.001) and 
respiratory diseases (p=0.038). 
Conclusions: Our results indicate a causal effect of smoking intensity on all-cause mortality and death 
by neoplasms and respiratory diseases. There was weaker evidence of a causal effect of smoking 
intensity on death by circulatory diseases.  






The association between tobacco smoking and increased mortality has been recognized for several 
decades (1). The association with cardiovascular diseases, cancer and respiratory diseases is well 
established (2, 3), and suggestive evidence exists for associations with several other diseases (4). 
There is a clear dose-response relationship between smoking and mortality (5, 6), and risk attenuates 
after smoking cessation (7). Although there may be health benefits from reducing tobacco 
consumption from high to low intensity, the effect seems to be small (8, 9) and even long-term very 
low intensity smoking has recently been associated with mortality (6) and cardiovascular diseases 
(10). 
The prevalence of heavy smoking has decreased over time in high income countries (11), while the 
prevalence of low intensity smoking has been more stable, thereby constituting a larger share of 
smokers (12). However, there is a clear social gradient in smoking (13), and smoking intensity is also 
higher among individuals with lower educational attainment (14). Moreover, smoking is associated 
with other health behaviours, and diseases onset could motivate smoking cessation. Residual 
confounding and reverse causality are therefore critical issues in studies of consequences of smoking.  
The presumed causality between smoking and all-cause mortality has been supported by a study 
using Mendelian randomisation (15, 16). Two single nucleotide polymorphisms (SNPs) rs1051730 and 
rs16969968 are strongly associated with tobacco consumption among smokers. This association is 
believed to be causal for rs16969968 and the two SNPs are in perfect linkage disequilibrium with 
each other and considered interchangeable (17). They are located in the CHRNA5-A3-B4 nicotinic 
receptor gene cluster, and each additional copy of the effect allele corresponds to about one 
additional cigarette per day among smokers, with even stronger associations observed for objective 
measures of tobacco consumption (18). The rs1051730 can thus, under the assumptions that the risk 




through smoking behaviour,  serve as an uncounfounded measure of smoking intensity (16). As 
smoking intensity can only affect mortality among smokers, we would expect associations between 
the SNP and mortality among ever smokers only. Never smokers can therefore be used as a negative 
control population, and any association between the SNP and outcomes among never smokers 
would suggest that the SNP is not a valid instrument for smoking intensity (19). However, 
stratification on smoking status could also induce collider bias if the SNP is associated with smoking 
initiation or cessation (20).  
We aimed to expand the existing literature by assessing the evidence of a causal relationship 
between smoking intensity and cause-specific as well as all-cause-mortality, using Mendelian 
randomisation (16).  
Methods 
Study design 
We performed Mendelian randomisation analyses of the associations between the single nucleotide 
polymorphism rs1051730 and all-cause and cause-specific mortality in two different study cohorts; 
the second wave of the Nord-Trøndelag Health Study (the HUNT2 Study 1995-97) and the UK 
Biobank (2006-2010). We subsequently meta-analysed the effect estimates. For comparison, we also 
estimated the association between self-reported smoking and mortality. Further details about the 
study populations and genotyping can be found in the web appendix. 
Smoking behaviour 
For analyses of self-reported smoking status, we categorised participants as never smokers, former 
smokers, current low intensity smokers (<10 cigarettes per day), medium intensity smokers (10-19 
cigarettes per day) or high intensity smokers (20 or more cigarettes per day). For the main Mendelian 




avoid potential collider bias. However, assuming that the effects of smoking intensity on mortality 
are reversible, we would expect stronger association among current compared to former smokers. 
We therefore additionally categorized smokers in five subgroups based on time since smoking 
cessation: current smokers, former smokers who quit less than 5 years, 5-9 years, 10-19 years or ≥ 20 
years before baseline, respectively.     
Outcome 
Date and cause of death until December 31st 2012 were collected from the Cause of Death Registry in 
Norway and until June 2017 in the UK. We defined all-cause mortality as death from any cause. To 
identify specific causes of death, we first recoded cause of death from ICD-9 to ICD 10 (21) for a total 
of 13 HUNT2-participants who died before 1996. Second, we categorised causes of death according 
to the European short list of causes of death (see Supplementary Table S1) (22).  
We excluded diseases of blood, blood-forming organs and immune system, skin and subcutaneous 
tissue, complications of pregnancies, conditions originating in the perinatal period and congenital 
malformations and chromosomal abnormalities (ICD-10 codes D50-D89, O00-Q99) from the analyses 
of cause-specific mortality, due to few deaths from these causes. 
Statistical analyses 
We assessed the statistical evidence of an association between number of effect alleles and possible 
confounders within strata of smoking status, using linear regression for continuous variables and chi 
square test for categorical variables.   
All associations were analysed separately within the UK Biobank and the HUNT2 cohorts, and 
estimates from the two cohorts were subsequently meta-analysed. A random effects model was 
used for associations with self-reported smoking, whereas associations with the genetic instrument 




because I2 indicated substantial heterogeneity for several causes of death.  We performed analyses 
using complete cases in Stata 15.0 and R (R Core Team, 2014). 
Associations with self-reported smoking 
We analysed the association between self-reported smoking status and mortality using Cox 
proportional hazard models with age as the time scale, adjusted for alcohol intake and in strata of 
education and sex. The association between smoking and body mass index is likely bidirectional; as 
smoking is associated with lower body mass index, a high body mass index can motivate smoking 
initiation (23, 24). We considered the mediating effect to be more important than the confounding 
effect in a setting with mostly middle-aged study participants, and hence did not adjust for body 
mass index. Different causes of mortality were assessed in separate models, and participants were 
censored at time of death from any other cause than the one used as an outcome in any given 
model, as well as at time of emigration or end of follow-up. We assessed the proportional hazards 
assumption using Schoenfeld residuals and visual inspection of log-log plots. Due to indication of 
non-proportionality, we performed additional analyses in strata of age. 
Mendelian randomisation 
We similarly analysed the association between the rs1051730 effect allele and death using Cox 
proportional hazards models with age as the time scale, and stratified by sex. As the association 
between the SNP and number of cigarettes smoked was consistent with an additive effect, we 
treated number of effect alleles as a continuous variable in the analyses.  
As smoking intensity can only affect mortality among smokers, we would expect associations 
between the SNP and mortality among ever smokers only. We therefore performed analyses 
separately for ever smokers and never smokers, and we report the statistical evidence of 




Shoenfeld’s residuals did not provide statistical evidence of non-proportional hazards for the 
association between the SNP and mortality in strata of smokers/never smokers. We still examined 
the association separately before and after age 80 as visual inspection of log-log plots indicated 
possible violation of the proportional hazards assumptions. These analyses were performed in the 
HUNT Study only, as there were no deaths after age 80 in the UK Biobank sample. 
To assess the potential benefit of smoking cessation, we also performed Mendelian randomisation 
analyses separately for five groups based on current smoking status and time since smoking 
cessation for former smokers. 
Results 
Our study sample included 56,019 participants from the HUNT2 Study and 337,103 participants from 
the UK Biobank. Of these, 11,303 and 9634 participants, respectively, died within follow-up. The 
most common causes of death were neoplasms and diseases of the circulatory system 
(Supplementary Table S1). Participants in the HUNT2 Study were followed for up to 17.4 years , and 
median age at death was 82 years (interquartile range 75-88) compared to a maximum of 11 years of 
follow-up and a median age at death of 67 years (interquartile range 62-70) in the UK Biobank 
sample. 
We confirmed the association between rs1051730 and intensity of smoking; for each effect allele, 
current smokers smoked on average 0.7 cigarettes (95% confidence interval (CI) 0.5-0.8) more per 
day in the HUNT2 Study and 1.0 (95% CI 0.9 to 1.1) cigarettes more per day in the UK Biobank 
sample, with a near linear increase in number of cigarettes smoked per effect allele alleles. The SNP 
was also associated with being a current rather than former smoker (p<0.001) and with lower age at 
participation among ever smokers (p=0.005 in the HUNT Study, p=0.002 in the UK Biobank). Possible 




to S5). For each risk allele, the odds of ever having smoked daily increased with 2% (95% CI 1-3%, 
p<0.001) and 4% (95% CI 1-6%, p=0.005) in the UK Biobank Study and the HUNT Study, respectively. 
Self-reported smoking 
We found a clear dose-response relationship between self-reported smoking and all-cause mortality, 
mortality by neoplasm, circulatory and respiratory diseases, diseases of the digestive system and 
external causes of death (Figure 1). Former smokers had an intermediate risk between never and low 
intensity smokers for all of these causes of death, except that there was no increased risk of death by 
external causes for former compared to never smokers. We found indication of non-proportionality 
of hazards for all-cause mortality and death by mental disorders, neurological, circulatory, and 
respiratory diseases. Additional analyses indicated weaker associations between smoking and 
mortality at older ages (Supplementary Tables S8 and S9).  
Figure 1: Associations between smoking status (given as never smoker, former smoker or by number 
of cigarettes smoked per day among current smokers) and mortality, results from a random effects 




2010). Graphs are truncated at hazard ratio=0.5
 
Mendelian randomisation analyses 
Mendelian randomisation analyses indicated a causal mechanism behind the observed association 
between smoking intensity and all-cause mortality among ever smokers (hazard ratio (HR) 1.09, 95% 
CI 1.06 to 1.11 per risk allele – see Figure 2). Furthermore, Mendelian randomisation results 
supported a causal effect of smoking intensity on death by neoplasms (HR 1.11, 95% CI 1.06 to 1.15 
per risk allele) and respiratory diseases (HR 1.15, 95% CI 1.05 to 1.26 per risk allele). Number of effect 
alleles was not associated with higher mortality from either of these causes among never smokers 




Figure 2: Associations between number of smoking increasing alleles of rs1071530 and mortality, 
results from a fixed effect meta-analysis of estimates from the HUNT2 Study (1995-1997) and UK 
Biobank (2006-2010). 
Each effect allele was associated with 6% (95% CI 1 to 11%) increased hazard rate of death by 
circulatory diseases among ever smokers. The effect estimate among never smokers was only 
marginally smaller (HR 1.03, 95% CI 0.98-1.09), with weak statistical evidence of a difference (p for 
difference 0.568). In additional analyses, this association among never smokers was only found 
among those 80 years or older in the HUNT2 Study (Supplementary Table S12 and Supplementary 
Figure S8). Furthermore, we found some statistical evidence that the association between effect 
alleles and mortality by musculoskeletal diseases differed between smokers and non-smokers (p for 
difference 0.038), but there was only weak evidence of an association among ever smokers (HR 1.28, 





For all other causes of death, we did not find strong statistical evidence of either associations 
between effect alleles and mortality among ever smokers or a stronger association among ever 
compared to never smokers.  
There was substantial heterogeneity between the estimates from the HUNT2 Study and the UK 
Biobank for several outcomes (I2 up to 89%). Random effects meta-analyses gave similar effect 
estimates as fixed effect meta-analyses, but with lower precision (Supplementary Figure S2). 
Furthermore, we found low heterogeneity between the HUNT2 Study and the UK Biobank in the 
association among current smokers, whereas there was substantial heterogeneity among former 
smokers (Figure 3 and Supplementary Figures S3-S14), and analyses of current smokers supported a 
causal effect of smoking intensity on all-cause mortality and death by neoplasm and respiratory 
diseases. We found only weak statistical evidence of an association between effect alleles and death 
by circulatory disease among current smokers (HR 1.05, 95% CI 0.97-1.13, p=0.213), but with low 
heterogeneity between the HUNT2 Study and the UK Biobank. For all-cause mortality and death by 
neoplasms, meta-analyses indicated that the excess risk associated with each effect allele attenuated 
with time, whereas the results were not clear-cut for the other causes of death (Figure 3 and 
Supplementary Figures S3-S14). The association between effect alleles and death by circulatory 





Figure 3: Associations between number of smoking increasing alleles of rs1071530 and all-cause 
mortality, results from a fixed effect meta-analysis of estimates from the HUNT2 Study (1995-1997) 
(n=55.593) and UK Biobank (2006-2010). Results are presented separately by smoking status.  
 
Discussion 
Using data from two large-scale cohort studies, we observed a clear dose-response relationship of 
self-reported smoking with all-cause mortality and mortality by neoplasm, circulatory diseases, 
respiratory diseases, diseases of the digestive system, and external causes of death. Mendelian 
randomisation analyses indicated a causal mechanism behind the observed association for all-cause 
mortality as well as for death by neoplasms and respiratory diseases. We found weaker evidence for 




Strengths and limitations 
The validity of Mendelian randomisation analyses relies on three main assumptions: 1) the genetic 
instrument must be associated with the exposure of interest, 2) it must only be associated with the 
outcome through the exposure of interest, and 3) it must be independent of confounders. The 
association between rs157030 and smoking intensity has been established previously, and was 
confirmed in our study samples. The second and third assumptions cannot be directly verified, but 
can be supported by lack of associations between effect alleles and known confounders and by use 
of negative controls (19). An association between effect alleles and age at participation among ever 
smokers is to be expected, as smoking intensity increases mortality. The lack of associations between 
effect alleles and mortality among never smokers support the interpretation of a causal effect of 
smoking intensity on all-cause mortality, as well as death by neoplasms and respiratory diseases. A 
full instrumental variable estimation of the causal effect per cigarette smoked was not possible as 
the number of cigarettes smoked does not fully describe the effect of the SNP on tobacco 
consumption (18). 
In the Mendelian randomisation analyses, we adjusted for age and sex only, both of which had 
complete data, and missing on smoking status was a negligible problem. However, there is the 
potential for misclassification of the self-reported smoking variables. Misclassification of ever 
smokers as never smokers would bias the use of never smokers as a negative control; however, we 
have no indication of this from the analyses of all-cause mortality. Dates and causes of deaths were 
collected from national registries, we thus had the best information available about causes of death; 
however, as causes of death are rarely determined based on post-mortem examinations, we cannot 
exclude misclassifications in causes of death either. This study gives a broad overview of the 
associations between a genetic variant associated with smoking intensity and mortality, but 




Furthermore, whereas genetic variants are determined at conception, study participants did not 
enter the studies until adulthood. As we lack information about the association between effect 
alleles and mortality before study inclusion, there is a possibility that lower survival among exposed 
individuals could bias the results (25).  
Participation in the HUNT2 Study was about 70% (26), and the HUNT2 Study is fairly representative 
of the general population, but despite this, non-participants in the HUNT2 Study tend to have 
somewhat higher mortality as compared to participants (27). In contrast, participation in the UK 
Biobank was only about 5%, suggesting a higher selection to participation (28). Representative 
samples are not a prerequisite for valid associations in longitudinal studies (29). Still, selective 
participation could induce bias (30). While the low mortality associated with effect alleles among 
former smokers in the UK Biobank sample could be due to selection bias, the consistency of 
estimated associations between the two samples among current smokers suggest that selection bias 
is a lesser problem for this group of participants.   
We found a weak association of the SNP with smoking initiation and stronger evidence of an 
association with smoking cessation. However, we found only weak evidence of associations between 
the SNP and important confounders within strata of smoking status. This weighs against any 
important collider bias being introduced by stratification, but we still cannot exclude it (17).  
Comparison with other studies 
Evidence of a causal effect of smoking intensity on all-cause mortality, deaths by neoplasms and 
respiratory diseases is consistent with existing knowledge about the consequences of smoking (3). A 
possible effect of smoking intensity on death by musculoskeletal and connective tissue diseases 
should not be given much emphasis, as the estimates were imprecise and inconsistent between 
methods. On the other hand, smoking has previously been associated with rheumatoid arthritis and 




Although smoking is also a well-established risk factor for circulatory diseases, our findings regarding 
a causal link were not conclusive. As effect estimates were similar among never compared to ever 
smokers, we cannot exclude pleiotropic effects of the SNP as an explanation. However, the finding of 
an association between the effect allele and death from circulatory diseases among never smokers 
was inconsistent, and the modest association found in ever smokers might therefore still represent a 
causal effect of smoking intensity on death by circulatory diseases. The gradient in risk associated 
with self-reported smoking intensity is also gentler for death by circulatory diseases, compared to 
neoplasms and respiratory diseases. This is in accordance with a recent review, in which smoking just 
one cigarette per day was found to confer up to half of the excess relative risk of cardiovascular 
diseases associated with smoking 20 cigarettes per day (10). Finding evidence of a weak causal effect 
only is thus consistent with the effects of smoking on circulatory diseases depending more on 
smoking status than on smoking intensity. 
Our results did not indicate causality in the associations of smoking with infectious diseases, diseases 
of the digestive system, and renal failure previously identified by Carter et al (4), although, again, it is 
important to bear in mind that the SNP we used is mainly an instrument of smoking intensity, not 
smoking status.   
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The HUNT Study 
The HUNT Study is a large total population-based health study in which all inhabitants of 
Nord-Trøndelag County aged 20 years or older have been invited to participate. In the second 
wave of the study (the HUNT2 Study, 1995-97), 69.5% of the invited participated (n=65,237) 
(1). Questionnaires covered a range of topics regarding health, diseases, behavioural risk 
factors and social and socioeconomic conditions, anthropometric data was measured and non-
fasting venous blood samples were drawn (1). The study sample consisted of 56,019 
individuals with genotype data (Supplementary Figure S1).  
The UK Biobank 
The UK Biobank is a national health resource, which recruited individuals at assessment 
centres located across the UK from 2006 to 2010 (2).  In total, data was collected on 502,647 
participants aged between 40 and 69 years. Collected measures cover a wide range of 
physical, cognitive and mental health outcomes as well as many risk factors including 
smoking behaviour. After restricting individuals to white British ancestry, removing related 
individuals and applying standard genotype exclusions, 337,103 individuals were available 
for the current analysis. Further details of standard exclusion criteria are presented elsewhere 
(3).   
Genetic information 
The rs1051730 SNP was genotyped in DNA extracted from blood samples collected at 
HUNT2, using a TaqMan assay (Assay ID: C_9510307_20, Applied Biosystems, USA) on an 
Applied Biosystems 7900HT Fast Real-Time PCR System, as described earlier (4). The 
genotyping success rate was 99.3% (call rate cut-off 90%) and the genotype frequencies were 
in agreement with HapMap-CEU data (MAF = 0.335 and 0.389, respectively) (4).  
In the UK Biobank, blood samples were collected at the initial assessment centre. For 49,979 
participants, genotyping was conducted using the Affymetrix UK BiLEVE Axiom array and 
for the remaining 438,398 participants, the Affymetrix UK Biobank Axiom® array was used.  
Imputation and initial quality control steps were performed by the Wellcome Trust Centre for 
Human Genetics (5).(3). The rs1051730 SNP call rate was 100% and MAF = 0.328.  
Study variables 
How smoking was assessed 
In each study cohort, smoking status at baseline was reported as never smoker, former smoker 
or current smoker of cigarettes, cigars or pipe. We excluded those who reported cigar or pipe 
smoke only.  Current and former smokers were asked about the average number of cigarettes 
consumed per day, and former smokers reported the number of years since smoking cessation. 
Participants in the UK Biobank were asked to report 1 cigarette per gram of hand-rolled 
tobacco or 30 cigarettes per ounce.  
Covariates in observational analyses 
We categorized level of education at baseline as primary, secondary and tertiary education 
based on data from national registries in HUNT2 and self-reported in the UK Biobank. 
Participants in HUNT2 were asked if they were teetotallers, and about frequency of alcohol 
intake per month. Participants in the UK Biobank reported frequency of alcohol intake 
according to the following categories: never, on special occasions, 1-3 times a month, 
once/twice a week, three-four times a week or daily/almost daily. We categorized frequency 
of alcohol intake as never, on special occasions (including those who did not state to be a 
teetotaller, but still reported 0 occasions per month), monthly (1-3 times a month), weekly 
(including once a week to four times a week or 4-15 times a month) or daily/almost daily 
(including 16 or more times a month).  
Statistical analyses 
Conditioning on smoking status and collider bias 
 
A mutation in rs1051730 has been found to be associated with smoking intensity. This 
association is likely mediated through modifications of nicotinic acetylcholine receptors (6). 
Initiation of smoking can be considered a prerequisite for rs1051730 to increase smoking 
intensity; in a society fee from tobacco consumption, rs1051730 could not affect smoking 
intensity. Smoking cessation could, on the other hand, be considered a consequence of 
smoking intensity; high intensity smokers tend to be less inclined to cease smoking (7). This 
situation is illustrated in Supplementary Figure S1. According to this DAG, smoking initiation 
is not a consequence of smoking intensity and conditioning on smoking intensity should 
therefore not create any collider bias. Smoking cessation is, on the other hand, downstream of 




Despite the argument that rs1051730 can only affect smoking intensity in the presence of 
tobacco consumption, we found indication of an association between the SNP and the 
likelihood of smoking initiation (OR 1.04, 95% CI 1.01-1.06 in the HUNT2 Study). Those 
who report to never have smoked daily might include individuals who tried smoking, but 
never took up smoking at a daily basis. Assuming that a substantial part of both study 
populations had ever tried smoking, it is therefore possible that the presence of the effect 
allele affected the likelihood to take up daily smoking, i.e. to initiate smoking. Reporting to be 
a never smoker could thus be a consequence of the effect allele, downstream to the very 
lowest levels of smoking intensity. Yet, the association between rs1051730 was weak, as ever 









corresponds to a mere one percentage point difference in frequency of ever smoking per effect 
allele. Given a weak to moderate association between the risk factor and the collider, 
conditioning on a collider will usually be a minor source of bias in Mendelian Randomisation 
studies (8).  
If conditioning on smoking status introduced a collider bias, we would expect to find evidence 
of an association between rs1051730 and measured confounders in strata of smokers. Results 
of these analyses are presented in Supplementary Tables S2-S5. We found weak statistical 
evidence that number of effect alleles were associated with education and alcohol intake 
 
It is therefore unlikely that a collider bias introduced by conditioning on smoking initiation 
would introduce an important bias. The bias from conditioning on smoking cessation would 
likely be larger, as the association between the SNP and smoking cessation is greater (…). 
Considering the lack of association between the SNP and potential confounders in groups of 
ever/never smokers and former/current smokers, we consider it unlikely that our results are 










Supplementary Table S1: Coding of causes of death, and number of deaths per cause in the 












deaths in  
the UK 
Biobank 
1. Infectious and parasitic diseases A00-B99 221 83 
2. Neoplasms C00-D48 3138 5679 
3. Diseases of the blood and blood-forming 
organs and certain disorders involving the 
immune mechanism 
D50-D89 32 22 
4. Endocrine, nutritional and metabolic diseases E00-E89 258 71 
5. Mental and behavioural disorders F01-F99 319 78 
6. Diseases of the nervous system and the sense 
organs 
G00-H95 339 312 
7. Diseases of the circulatory system I00-I99 4603 1979 
8. Diseases of the respiratory system J00-J99 866 535 
9. Diseases of the digestive system K00-K92 284 383 
10. Diseases of the skin and subcutaneous tissue L00-L99 13 8 
11. Diseases of the musculoskeletal 
system/connective tissue 
M00-M99 65 53 
12. Diseases of the genitourinary system N00-N99 240 42 
13. Complications of pregnancy, childbirth and 
puerperium 
O00-O99 0 0 
14. Certain conditions originating in the perinatal 
period 
P00-P96 0 0 
15. Congenital malformations and chromosomal 
abnormalities 
Q00-Q99 9 13 
16. Symptoms, signs, ill-defined causes R00-R99 458 51 
17. External causes of morbidity and mortality V01-Y89 457 43 
 Missing cause of death in registry  1  
 Total  11 303 9634 
 
Supplementary Figure S1: Flow-chart showing how the study sample was derived and the 
number of participants included in the different analyses – The HUNT2 Study (1995-97) 
 
 
* This participant was missing date of participation and was therefore assigned the median date of 
participation as a start of follow-up. However, the participant died before the median participation 




Invited to participate in HUNT2 
N=94,194 




Smoked pipe/cigar only n=605 
Missing smoking status n=39 
Missing follow-up time n=1* 
Included in MR according to time since smoking cessation 
n=55,593 
Included in main MR analyses 
n=56,019 
Missing time since smoking 
cessation n=426 
Missing data for observational 
analyses n=3497 
Included in observational analyses 
n=52,561 
Supplementary Table S2: Baseline characteristics of 56,019 participants in the HUNT2 Study 
according to smoking status and number of rs1051730 effect alleles 
  
Never smokers 
   
Ever smokers 
  
           
  
0 1 2 p-value 
 
0 1 2 p-value 
Study sample (n) 
 
11,138 10,866 2,743 
  
13,712 13,958 3602 
 
Cigarettes per day 
(mean) 
     
11.1 11.7 12.2 <0.001 
     Missing (n)       1133 1147 277  
Smoking status (%)a           
     Current       52 55 58  
     Former       48 45 43 <0.001 
Men (%) 
 
41 41 41 0.866 
 
53 52 51 0.118 
Age (mean)  49.2 49.3 49.1 0.980  50.5 50.1 49.7 0.005 
Education (%) 
         
     Primary 
 
33 33 32 
  
39 40 40 
 
     Secondary 
 
41 41 42 
  
46 46 45 
 
     Tertiary 
 
26 26 26 0.723 
 
15 15 15 0.478 
     Missing (n)  560 586 151   603 630 155  
Alcohol intake (%) 
          
     Never 
 
20 19 19 
  
7 7 7 
 
     Special occasions 
 
28 29 30 
  
26 27 27 
 
     Monthly 
 
35 34 35 
  
39 39 40 
 
     Weekly 
 
17 17 16 
  
28 27 26 
 
     Daily/almost daily  0 0 0 0.331  1 1 1 0.558 
     Missing (n) 
 
510 537 138 
  
732 784 207 
 
           
 
a Smoking status was missing for 39 individuals 
Supplementary Table S3: Baseline characteristics of 31,272 ever smokers in the HUNT2 Study 
according to current smoking status and number of rs1051730 effect alleles  
  
Former smokers  
   
Current smokers 
  
           
  
0 1 2 p-value 
 
0 1 2 p-value 
Study sample (n) 
 
6536 6284 1529   7176 7674 2073  
Cigarettes per day 
(mean) 
11.5 12.0 12.3 <0.001  10.7 11.4 12.1 <0.001 
     Missing (n)  891 887 212   242 260 65  
Men (%) 
 
60 60 58 0.117  46 45 46 0.733 
Age (mean)  54.3 54.0 53.9 0.275  47.0 47.0 46.5 0.370 
Education (%)          
     Primary 
 
39 39 41   39 40 39  
     Secondary 
 
43 42 40   48 48 48  
     Tertiary 
 
18 18 19 0.263  13 12 13 0.260 
     Missing (n)  304 324 67   299 306 88  
Alcohol intake (%) 
  
        
     Never 
 
8 7 8   6 6 6  
     Special occasions 
 
28 29 28   24 25 26  
     Monthly 
 
36 36 38   42 41 41  
     Weekly 
 
28 27 25   28 27 27  
     Daily/almost daily  1 1 1 0.356  1 1 1 0.634 
     Missing (n) 
 
329 324 90   403 460 117  
           
  
Supplementary Table S4: Baseline characteristics of 335,918 participants in the UK Biobank 
according to smoking status and number of rs1051730 effect alleles 
  
Never smokers 
   
Ever smokers 
  
           
  
0 1 2 p-
value 
 
0 1 2 p-value 
Study sample (n) 
 
82,141 81,599 20,338 
  




     
14.88 15.90 16.72 <0.001 
     Missing (n)       3807 3371 739  
Smoking status (%)a           
     Current       22 22 22  
     Former       78 78 78 0.055 
Men (%) 
 
42 41 41 0.121 
 
52 52 52 0.549 
Age (mean)  56.1 56.2 56.2 0.092  57.8 57.7 57.6 0.002 
Education (%) 
         
     Primary 
 
14 14 14 
  
21 21 20 
 
     Secondary 
 
51 50 50 
  
51 52 52 
 
     Tertiary 
 
36 36 36 0.768 
 
27 27 28 0.021 
     Missing (n)  683 704 202   634 685 133  
Alcohol intake (%) 
          
     Never 
 
7 7 7 
  
5 6 6 
 
     Special occasions 
 
11 12 11 
  
9 9 9 
 
     Monthly 
 
12 13 12 
  
9 10 10 
 
     Weekly 
 
53 52 53 
  
49 48 48 
 
     Daily/almost daily  16 16 16 0.150  28 28 28 0.074 
     Missing (n) 
 
33 47 16 
  
47 55 13 
 
           
 
a Smoking status was missing for 1185 individuals 
  
Supplementary Table S5: Baseline characteristics of 151,840 ever smokers in the UK Biobank 
Study according to current smoking status and number of rs1051730 effect alleles  
  
Former smokers  
   
Current smokers 
  
           
  
0 1 2 p-value 
 
0 1 2 p-value 
Study sample (n) 
 
53,662 52,137 12,679   14,907 14,825 3,630  
Cigarettes per day (mean) 18.5 19.5 20.4 <0.001  14.9 15.9 16.7 <0.001 
     Missing (n)  20,694 18,814 4,255   3,807 3,371 739  
Men (%) 
 
51 52 51 0.514  54 54 54 0.912 
Age (mean)  58.5 58.4 58.4 0.033  55.1 55.1 54.8 0.066 
Education (%)          
     Primary 
 
20 20 19   25 25 24  
     Secondary 
 
51 51 51   53 54 55  
     Tertiary 
 
29 29 30 0.033  22 22 22 0.541 
     Missing (n)  478 506 93   156 179 40  
Alcohol intake (%) 
  
        
     Never 
 
5 5 5   7 8 7  
     Special occasions 
 
8 9 8   12 12 14  
     Monthly 
 
8 9 9   11 11 12  
     Weekly 
 
50 49 49   43 42 41  
     Daily/almost daily  28 28 29 0.286  27 27 27 0.003 
     Missing (n) 
 
27 27 7   20 28 6  
 
  
Supplementary Table S6: Associations between self-reported smoking status and all-cause and 
cause-specific mortality in the HUNT2 Study (1995-97). N=52,561.  
 
Cause1 Smoking  Deaths HR 95 % CI   




 Former smoker  3181 1.28 1.21 - 1.35 
 <10 cig per day  1025 1.74 1.62 - 1.87 
 10-19 cig per day  1196 2.11 1.96 - 2.26 
 20+ cig/day  330 2.98 2.65 - 3.36 




 Former smoker  64 1.36 0.93 - 1.99 
 <10 cig per day  11 1.06 0.56 - 2.02 
 10-19 cig per day  20 2.57 1.52 - 4.36 
 20+ cig/day  4 3.20 1.13 - 9.10 




 Former smoker  944 1.37 1.24 - 1.52 
 <10 cig per day  320 1.81 1.58 - 2.06 
 10-19 cig per day  471 2.40 2.13 - 2.71 
 20+ cig/day  125 3.20 2.63 - 3.90 




 Former smoker  65 0.88 0.62 - 1.24 
 <10 cig per day  17 0.98 0.58 - 1.66 
 10-19 cig per day  17 0.99 0.57 - 1.70 
 20+ cig/day  5 1.47 0.58 - 3.73 




 Former smoker  80 1.29 0.93 - 1.79 
 <10 cig per day  20 1.35 0.83 - 2.19 
 10-19 cig per day  19 1.76 1.05 - 2.95 
 20+ cig/day  6 3.12 1.32 - 7.38 




 Former smoker  94 1.19 0.88 - 1.61 
 <10 cig per day  29 1.42 0.93 - 2.15 
 10-19 cig per day  26 1.19 0.76 - 1.88 
 20+ cig/day  7 1.49 0.67 - 3.30 




 Former smoker  1298 1.21 1.11 - 1.31 
 <10 cig per day  402 1.66 1.49 - 1.87 
 10-19 cig per day  363 1.71 1.52 - 1.94 
 20+ cig/day  99 2.46 1.99 - 3.04 
Respiratory 





 Former smoker  240 1.69 1.37 - 2.08 
 <10 cig per day  110 3.50 2.75 - 4.46 
 10-19 cig per day  106 4.28 3.32 - 5.51 
 20+ cig/day  40 9.66 6.71 - 13.91 




 Former smoker  67 1.35 0.94 - 1.92 
 <10 cig per day  29 2.24 1.45 - 3.46 
 10-19 cig per day  43 3.87 2.58 - 5.81 
 20+ cig/day  5 2.59 1.02 - 6.58 




connective tissue  Former smoker  75 0.72 0.36 - 1.46 
 <10 cig per day  12 0.89 0.33 - 2.38 
 10-19 cig per day  10 1.33 0.54 - 3.26 
 20+ cig/day  3 1.14 0.15 - 8.80 




 Former smoker  2 1.37 0.96 - 1.96 
 <10 cig per day  0 1.02 0.55 - 1.88 
 10-19 cig per day  0 1.21 0.61 - 2.39 
 20+ cig/day  0 2.43 0.75 - 7.90 




 Former smoker  127 1.39 1.05 - 1.82 
 <10 cig per day  24 1.21 0.78 - 1.88 
 10-19 cig per day  48 2.52 1.75 - 3.62 
 20+ cig/day  11 2.48 1.30 - 4.74 
External causes Never smoker  168 1.00 1.00  1.00 
 Former smoker  98 1.13 0.85 - 1.50 
 <10 cig per day  42 1.86 1.30 - 2.65 
 10-19 cig per day  64 2.16 1.57 - 2.99 
 20+ cig/day  23 3.26 2.03 - 5.23 
 
1 Each cause of death is examined in a separate model with age as the time scale, adjusted for alcohol 
and in strata of sex and education. 
Supplementary Table S7: Associations between self-reported smoking status and all-cause and 
cause-specific mortality – the UK Biobank (2006-10).  
 
Cause1 Smoking  Deaths HR 95 % CI   




 Former smoker  3938 1.44 1.37 - 1.51 
 <10 cigarettes per day  187 2.18 1.88 - 2.53 
 10-19 cigarettes per day  557 2.76 2.52 - 3.02 
 20+ cigarettes/day  738 3.79 3.49 - 4.11 




 Former smoker  26 1.16 0.68 - 1.98 
 <10 cigarettes per day  1 1.35 0.18 - 9.93 
 10-19 cigarettes per day  8 4.86 2.21 - 10.70 
 20+ cigarettes/day  12 8.13 4.07 - 16.27 




 Former smoker  2428 1.45 1.36 - 1.54 
 <10 cigarettes per day  108 2.00 1.65 - 2.43 
 10-19 cigarettes per day  315 2.59 2.30 - 2.92 
 20+ cigarettes/day  408 3.62 3.25 - 4.03 




 Former smoker  31 1.18 0.71 - 1.96 
 <10 cigarettes per day  0     
 10-19 cigarettes per day  3 1.20 0.36 - 3.96 
 20+ cigarettes/day  3 1.11 0.33 - 3.69 




 Former smoker  29 1.12 0.66 - 1.88 
 <10 cigarettes per day  2 3.02 0.72 - 12.69 
 10-19 cigarettes per day  1 0.62 0.08 - 4.59 
 20+ cigarettes/day  8 5.26 2.37 - 11.69 




 Former smoker  115 0.93 0.73 - 1.19 
 <10 cigarettes per day  6 1.58 0.70 - 3.57 
 10-19 cigarettes per day  5 0.58 0.24 - 1.41 
 20+ cigarettes/day  13 1.60 0.90 - 2.84 




 Former smoker  860 1.55 1.39 - 1.72 
 <10 cigarettes per day  46 2.89 2.14 - 3.90 
 10-19 cigarettes per day  132 3.22 2.67 - 3.89 
 20+ cigarettes/day  163 3.84 3.22 - 4.58 
Respiratory 
diseases 




Former smoker  239 2.10 1.69 - 2.61 
 <10 cigarettes per day  12 3.57 1.98 - 6.46 
 10-19 cigarettes per day  50 5.83 4.20 - 8.11 
 20+ cigarettes/day  62 7.21 5.28 - 9.84 




 Former smoker  129 1.13 0.88 - 1.45 
 <10 cigarettes per day  8 2.14 1.05 - 4.38 
 10-19 cigarettes per day  30 3.20 2.14 - 4.78 
 20+ cigarettes/day  54 5.30 3.81 - 7.37 




connective tissue  Former smoker  28 2.38 1.30 - 4.38 
 <10 cigarettes per day  1 2.00 0.27 - 15.04 
 10-19 cigarettes per day  0     
 20+ cigarettes/day  1 0.90 0.12 - 6.89 




 Former smoker  20 1.69 0.86 - 3.33 
 <10 cigarettes per day  1 2.57 0.34 - 19.52 
 10-19 cigarettes per day  2 2.02 0.46 - 8.90 
 20+ cigarettes/day  1 1.06 0.14 - 8.11 




 Former smoker  11 0.81 0.39 - 1.70 
 <10 cigarettes per day  0     
 10-19 cigarettes per day  6 3.90 1.53 - 9.89 
 20+ cigarettes/day  10 5.72 2.58 - 12.70 




 Former smoker  12 0.77 0.37 - 1.59 
 <10 cigarettes per day  0     
 10-19 cigarettes per day  2 1.51 0.35 - 6.50 
 20+ cigarettes/day  3 2.36 0.68 - 8.18 
 
1 Each cause of death is examined in a separate model with age as the time scale, adjusted for alcohol 
and in strata of sex and education. 
 
  
Supplementary Table S8: Associations between self-reported smoking status and all-cause and cause-specific mortality –the HUNT2 Study (1995-
97). Analyses performed separately up to age 70, from age 70-85 and aged 85 onwards. N=52,561. 
 
   Before 70 years old  70-85 years old   85+ years old   
Cause1   Deaths HR 95% CI  Deaths HR 95% CI  Deaths HR 95% CI 
All-cause 
mortality2 
Never smoker  445 Ref     1482 Ref     2306 Ref    
Former smoker  462 1.34 1.17 - 1.53  1634 1.38 1.28 - 1.50  1085 1.15 1.05 - 1.26 
 <10 cig per day  223 2.01 1.70 - 2.37  559 1.88 1.70 - 2.07  243 1.44 1.26 - 1.65 
 10-19 cig per day  455 2.21 1.93 - 2.53  608 2.42 2.19 - 2.68  133 1.52 1.27 - 1.83 
 20+ cig/day  188 3.45 2.89 - 4.12  124 3.11 2.57 - 3.76  18 1.55 0.97 - 2.47 
                    
Infectious 
diseases 
Never smoker  3 Ref     32 Ref     66 Ref    
Former smoker  2 0.79 0.13 - 5.00  31 1.52 0.86 - 2.68  31 1.27 0.74 - 2.17 
 <10 cig per day  1 1.36 0.14 - 13.44  3 0.56 0.17 - 1.86  7 1.67 0.74 - 3.76 
 10-19 cig per day  6 4.42 1.04 - 18.78  12 2.99 1.47 - 6.07  2 0.85 0.20 - 3.62 
 20+ cigarettes/day  1 2.88 0.28 - 29.60  1 1.92 0.25 - 14.42  2 7.04 1.65 - 30.09 
                    
Neoplasms Never smoker  208 Ref     423 Ref     305 Ref    
 Former smoker  225 1.45 1.19 - 1.76  496 1.35 1.16 - 1.56  223 1.35 1.10 - 1.67 
 <10 cig per day  104 1.94 1.52 - 2.46  178 1.91 1.59 - 2.29  38 1.30 0.92 - 1.85 
 10-19 cig per day  225 2.39 1.97 - 2.91  212 2.54 2.13 - 3.03  34 2.24 1.54 - 3.25 
 20+ cig/day  80 3.57 2.73 - 4.67  45 3.25 2.36 - 4.47  0     
                    
Metabolic 
diseases 
Never smoker  14 Ref     51 Ref     59 Ref    
Former smoker  12 1.08 0.48 - 2.41  31 0.84 0.51 - 1.40  22 0.82 0.45 - 1.49 
 <10 cig per day  2 0.64 0.14 - 2.88  10 1.02 0.51 - 2.05  5 1.13 0.43 - 2.91 
 10-19 cig per day  6 0.91 0.34 - 2.43  10 1.24 0.61 - 2.52  1 0.46 0.06 - 3.43 
 20+ cig/day  2 1.02 0.23 - 4.60  3 2.58 0.78 - 8.59  0     
                    
Mental 
disorders2 
Never smoker  4 Ref     41 Ref     112 Ref    
Former smoker  1 0.34 0.04 - 3.11  36 1.47 0.87 - 2.49  43 1.27 0.82 - 1.96 
 <10 cig per day  2 2.25 0.40 - 12.56  7 1.09 0.48 - 2.48  11 1.56 0.82 - 2.97 
 10-19 cig per day  9 5.12 1.50 - 17.51  8 1.78 0.80 - 3.92  2 0.57 0.14 - 2.37 
 20+ cig/day  5 7.96 1.94 - 32.70  1 1.89 0.25 - 14.08  0     
                    
Nervous 
system2 
Never smoker  23 Ref     54 Ref     64 Ref    
Former smoker  13 0.86 0.42 - 1.74  45 1.07 0.68 - 1.68  36 1.58 0.94 - 2.64 
 <10 cig per day  11 2.31 1.10 - 4.84  16 1.44 0.81 - 2.57  2 0.41 0.10 - 1.70 
 10-19 cig per day  11 1.13 0.54 - 2.39  12 1.27 0.66 - 2.45  3 1.22 0.37 - 4.02 
 20+ cig/day  5 1.80 0.67 - 4.87  2 1.27 0.30 - 5.36  0     
                    
Circulatory 
diseases2 
Never smoker  106 Ref     628 Ref     1140 Ref    
Former smoker  127 1.33 1.02 - 1.73  701 1.38 1.22 - 1.56  470 1.02 0.90 - 1.17 
 <10 cig per day  64 2.43 1.77 - 3.33  228 1.82 1.56 - 2.14  110 1.34 1.10 - 1.65 
 10-19 cig per day  101 1.98 1.50 - 2.63  218 2.09 1.78 - 2.46  44 1.02 0.75 - 1.39 
 20+ cig/day  48 3.21 2.25 - 4.57  43 2.65 1.92 - 3.64  8 1.45 0.72 - 2.92 
                    
Respiratory 
diseases2 
Never smoker  10 Ref     82 Ref     164 Ref    
Former smoker  17 2.38 1.07 - 5.31  129 2.00 1.47 - 2.72  94 1.38 1.01 - 1.89 
 <10 cig per day  11 4.22 1.77 - 10.09  67 4.20 2.99 - 5.88  32 2.81 1.88 - 4.21 
 10-19 cig per day  14 3.27 1.42 - 7.52  71 5.70 4.05 - 8.01  21 3.58 2.20 - 5.82 
 20+ cig/day  18 17.00 7.43 - 38.88  19 9.84 5.81 - 16.67  3 3.84 1.20 - 12.27 
                    
Digestive 
system 
Never smoker  6 Ref     41 Ref     57 Ref    
Former smoker  8 1.70 0.58 - 5.04  29 1.10 0.64 - 1.87  30 1.56 0.91 - 2.68 
 <10 cig per day  2 1.12 0.22 - 5.65  15 1.97 1.07 - 3.65  12 3.18 1.65 - 6.14 
 10-19 cig per day  14 4.36 1.62 - 11.73  23 3.77 2.16 - 6.56  6 3.25 1.34 - 7.91 
 20+ cig/day  5 6.88 2.00 - 23.63             
                    





Never smoker  3 Ref     13 Ref     14 Ref    
Former smoker  2 0.69 0.11 - 4.35  8 0.73 0.28 - 1.95  5 0.71 0.21 - 2.40 
<10 cig per day  1 0.93 0.09 - 9.22  3 0.93 0.26 - 3.37  1 0.73 0.09 - 5.84 
10-19 cig per day  2 1.02 0.16 - 6.37  4 1.45 0.45 - 4.70  1 1.56 0.19 - 12.72 
 20+ cig/day        1 2.68 0.33 - 21.80       
                    
Genitourinary  Never smoker  4 Ref     35 Ref     72 Ref    
 Former smoker  0 0.00 0.00 - 0.00  42 1.78 1.05 - 3.01  33 1.15 0.69 - 1.91 
 <10 cig per day  1 1.36 0.14 - 12.97  4 0.69 0.24 - 1.99  7 1.35 0.60 - 3.02 
 10-19 cig per day        8 1.79 0.80 - 4.03  2 0.81 0.19 - 3.36 
 20+ cig/day  1 4.94 0.52 - 46.49        2 5.78 1.35 - 24.78 
                    
Ill-defined 
causes 
Never smoker  13 Ref     38 Ref     150 Ref    
Former smoker  20 1.49 0.73 - 3.04  43 1.51 0.92 - 2.47  64 1.33 0.91 - 1.93 
<10 cig per day  3 0.85 0.24 - 3.02  13 1.80 0.94 - 3.45  8 0.94 0.45 - 1.95 
 10-19 cig per day  21 2.69 1.32 - 5.48  20 3.25 1.81 - 5.83  7 1.72 0.78 - 3.78 
 20+ cig/day  5 1.85 0.64 - 5.36  6 5.21 2.07 - 13.11       
                    
External 
causes 
Never smoker  42 Ref     41 Ref     85 Ref    
Former smoker  34 1.32 0.82 - 2.11  35 1.27 0.76 - 2.12  29 0.86 0.52 - 1.42 
 <10 cig per day  20 2.15 1.25 - 3.72  13 1.83 0.96 - 3.50  9 1.58 0.77 - 3.22 
 10-19 cig per day  46 2.40 1.55 - 3.72  8 1.38 0.63 - 3.05  10 3.16 1.56 - 6.41 
 20+ cig/day  18 3.32 1.86 - 5.92  3 3.23 0.95 - 10.95  2 4.95 1.18 - 20.77 
 
1 Each cause of death is examined in a separate model with age as the time scale, adjusted for alcohol and in strata of sex and education. 
2 Non-proportionality indicated by Schoenfeld’s residuals when analysing all ages combined 
Abbreviations: cig=cigarettes  
Supplementary Table S9: Associations between self-reported smoking status and all-cause and cause-specific mortality –the UK Biobank (2006-
10). Analyses performed separately up to age 70 and aged 70 onwards.  
 
   Before 70 years old  From 70 years old* 
   Deaths HR 95% CI    Deaths HR 95% CI   
All-cause mortality Never smoker  3556 1 Ref    1047 1 Ref   
 Former smoker 4051 1.44 1.36 - 1.52  1443 1.42 1.31 - 1.54 
 <10 cig per day 201 2.30 1.95 - 2.72  54 2.39 1.82 - 3.13 
 10-19 cig per day 582 4.61 4.23 - 5.03  134 3.27 2.73 - 3.92 
 20+ cig/day  778 3.09 2.80 - 3.42  134 2.73 2.28 - 3.27 
Infectious diseases Never smoker  32 1 Ref    7 1 Ref   
 Former smoker 26 1.15 0.64 - 2.08  6 0.89 0.30 - 2.69 
 <10 cig per day 1      1 6.44 0.79 - 52.32 
 10-19 cig per day 9 7.67 3.66 - 16.09  1 11.00 2.81 - 43.14 
 20+ cig/day  13 5.74 2.59 - 12.74  3 3.02 0.37 - 24.60 
Neoplasms Never smoker  2173 1 Ref    637 1 Ref   
 Former smoker 2427 1.48 1.38 - 1.59  817 1.35 1.22 - 1.50 
 <10 cig per day 110 2.02 1.61 - 2.53  30 2.14 1.48 - 3.08 
 10-19 cig per day 319 4.06 3.60 - 4.58  71 3.42 2.72 - 4.31 
 20+ cig/day  413 2.84 2.49 - 3.25  83 2.40 1.88 - 3.07 
Metabolic diseases Never smoker  33 1 Ref    5 1 Ref   
 Former smoker 31 0.85 0.45 - 1.58  15 2.73 0.99 - 7.59 
 <10 cig per day 0 0.00 0.00 -   0     
 10-19 cig per day 3 1.17 0.28 - 4.93  0 4.40 0.51 - 37.86 
 20+ cig/day  3 1.77 0.54 - 5.83  1     
Mental disorders Never smoker  32 1 Ref    20 1 Ref   
 Former smoker 30 1.13 0.50 - 2.56  19 0.93 0.49 - 1.76 
 <10 cig per day 2      2 4.66 1.09 - 19.95 
 10-19 cig per day 1 7.69 2.90 - 20.37  0 2.46 0.57 - 10.59 
 20+ cig/day  8 1.30 0.17 - 9.98  2     
Nervous system Never smoker  156 1 Ref    56 1 Ref   
 Former smoker 116 0.83 0.61 - 1.14  53 1.00 0.68 - 1.46 
 <10 cig per day 6 1.85 0.75 - 4.54  1 0.82 0.11 - 5.90 
 10-19 cig per day 5 1.62 0.82 - 3.21  1 2.36 0.94 - 5.91 
 20+ cig/day  14 0.67 0.25 - 1.82  5 0.39 0.05 - 2.80 
Circulatory disease Never smoker  659 1 Ref    187 1 Ref   
 Former smoker 862 1.46 1.29 - 1.65  328 1.72 1.43 - 2.06 
 <10 cig per day 46 3.05 2.17 - 4.30  12 2.92 1.63 - 5.23 
 10-19 cig per day 131 5.04 4.18 - 6.08  35 3.21 2.11 - 4.88 
 20+ cig/day  169 3.51 2.82 - 4.37  25 3.87 2.70 - 5.56 
Respiratory disease Never smoker  129 1 Ref    66 1 Ref   
 Former smoker 240 2.59 1.93 - 3.47  108 1.66 1.21 - 2.26 
 <10 cig per day 12 4.85 2.33 - 10.09  4 3.48 1.40 - 8.64 
 10-19 cig per day 51 13.48 9.35 - 19.44  17 4.96 2.73 - 9.01 
 20+ cig/day  64 8.87 5.88 - 13.40  13 5.50 3.22 - 9.38 
Digestive system Never smoker  133 1 Ref    34 1 Ref   
 Former smoker 132 1.24 0.93 - 1.65  41 1.23 0.77 - 1.95 
 <10 cig per day 9 2.83 1.32 - 6.09  2 2.67 0.64 - 11.13 
 10-19 cig per day 31 8.76 6.26 - 12.25  6 1.48 0.35 - 6.16 




Never smoker  17 1 Ref    3 1 Ref   
Former smoker 29 1.76 0.87 - 3.57  12 4.81 1.34 - 17.26 
<10 cig per day 1 2.34 0.31 - 17.73  0     
 10-19 cig per day 0 1.20 0.16 - 9.13  0     
 20+ cig/day  1      0     
Genitourinary Never smoker  16 1 Ref    5 1 Ref   
 Former smoker 20 1.00 0.40 - 2.52  12 2.65 0.92 - 7.65 
 <10 cig per day 1      1 9.25 1.08 - 79.22 
 10-19 cig per day 2 1.70 0.22 - 13.26  0     
 20+ cig/day  1 3.21 0.71 - 14.48  0     
Ill-defined causes Never smoker  21 1 Ref    3 1 Ref   
 Former smoker 11 0.73 0.31 - 1.68  3 0.98 0.19 - 4.98 
 <10 cig per day 0      0     
 10-19 cig per day 6 8.32 3.82 - 18.12  0     
 20+ cig/day  10 5.25 2.08 - 13.24  0     
External causes Never smoker  21 1 Ref    2 1 Ref   
 Former smoker 12 0.89 0.42 - 1.88  1 0.49 0.04 - 5.50 
 <10 cig per day 0      0     
 10-19 cig per day 2 3.73 1.26 - 11.02  0     
 20+ cig/day  4 1.75 0.41 - 7.50  0     
 
 
Abbreviations: cig=cigarettes  
* There were no deaths after age 80 in the UK Biobank study sample  
Supplementary Table S10: Hazard ratios for all-cause and cause specific mortality per effect allele of rs1051730 in never smokers (N=24,747), and 
ever smokers (N=31,272). The HUNT2 Study (1995-97). 
 
 
 Never smokers 
 
 Ever smokers 
 
 









All-cause 4709 1.02 0.98 - 1.06 
 
6594 1.12 1.08 - 1.16 <0.001 
Infectious diseases 108 1.02 0.77 - 1.35 
 
113 1.13 0.86 - 1.49 0.576 
Neoplasms 1029 0.98 0.89 - 1.07 
 
2109 1.19 1.12 - 1.27 <0.001 
Endocrine diseases 138 1.22 0.96 - 1.55 
 
120 1.30 1.00 - 1.69 0.709 
Mental disorders 174 0.96 0.77 - 1.20 
 
145 0.91 0.71 - 1.18 0.777 
Neurological disorders 160 0.91 0.72 - 1.15 
 
179 1.00 0.80 - 1.25 0.552 
Cardiovascular diseases 2101 1.06 0.99 - 1.12 
 
2502 1.08 1.01 - 1.14 0.532 
Respiratory diseases 285 0.97 0.82 - 1.16 
 
581 1.26 1.12 - 1.42 0.011 
Diseases of digestive system 117 1.05 0.80 - 1.37 
 
167 1.05 0.84 - 1.32 0.979 
Musculoskeletal / connective 
tissue diseases 
            
Diseases of genitourinary system 121 0.93 0.71 - 1.21 
 
119 0.96 0.73 - 1.26 0.852 
Unknown cause 222 1.09 0.90 - 1.32 
 
236 1.06 0.87 - 1.28 0.814 
External causes 188 1.02 0.82 - 1.26 
 
269 1.10 0.92 - 1.32 0.515 
 
 
1 P for different association between rs1051730 and mortality depending on smoking status.   
Supplementary Table S11: Hazard ratios for all-cause and cause specific mortality per effect allele of rs1051730 in never smokers (N= 248,438), 
and ever smokers (N= 212,565) in the UK Biobank (2006-10) 
 Never smokers     Ever smokers     
 Deaths HR 95% CI  Deaths HR 95% CI  
All-cause mortality 3603 0.98 0.93 - 1.03  6031 1.05 1.01 - 1.09  
Infectious diseases 32 1.20 0.72 - 1.99  51 0.94 0.62 - 1.43  
Neoplasms 2202 1.00 0.94 - 1.07  3477 1.06 1.00 - 1.11  
Endocrine diseases 33 1.22 0.74 - 2.01  38 0.79 0.47 - 1.30  
Mental disorders 33 0.81 0.47 - 1.38  45 1.20 0.78 - 1.84  
Neurological disorders 162 0.88 0.70 - 1.12  150 1.06 0.84 - 1.35  
Cardiovascular diseases 663 0.96 0.86 - 1.08  1316 1.02 0.94 - 1.11  
Respiratory diseases 134 0.91 0.71 - 1.18  401 1.00 0.86 - 1.15  
Diseases of digestive system 134 0.82 0.63 - 1.07  249 1.11 0.93 - 1.34  
Musculoskeletal / connective 
tissue diseases 
18 1.01 0.50 - 2.01  35 1.55 0.97 - 2.49  
Diseases of genitourinary system 16 0.66 0.30 - 1.48  26 0.76 0.41 - 1.41  
Unknown cause 21 0.81 0.41 - 1.57  30 1.27 0.75 - 2.14  
External causes 21 2.01 1.10 - 3.68  22 0.95 0.51 - 1.80  





Supplementary Table S12: Hazard ratios for all-cause and cause specific mortality per effect allele of rs1051730 in ever smokers (N=31,272), 
analysed separately before and after the age of 80. The HUNT2 Study (1995-97). 
 
  
 Death before age 80 
 
Death after age 
80 
 
   
 
Deaths HR 95% CI  
  




All-cause 3446 1.15 1.09 - 1.21 
 
3148 1.09 1.04 - 1.15 0.197 
Infectious diseases 40 1.35 0.86 - 2.11 
 
73 1.02 0.72 - 1.46 0.343 
Neoplasms 1383 1.19 1.10 - 1.29 
 
726 1.19 1.07 - 1.33 0.984 
Endocrine diseases 59 1.58 1.10 - 2.28 
 
61 1.06 0.72 - 1.55 0.136 
Mental disorders 38 0.92 0.57 - 1.49 
 
107 0.91 0.68 - 1.23 0.978 
Neurological disorders 96 1.07 0.80 - 1.44 
 
83 0.91 0.65 - 1.28 0.485 
Cardiovascular diseases 1172 1.05 0.97 - 1.15 
 
1330 1.10 1.01 - 1.19 0.505 
Respiratory diseases 239 1.48 1.24 - 1.78 
 
342 1.12 0.96 - 1.31 0.024 
Diseases of digestive system 82 1.06 0.77 - 1.47 
 
85 1.04 0.75 - 1.44 0.922 
Diseases of genitourinary system 32 1.08 0.64 - 1.81 
 
87 0.91 0.66 - 1.27 0.601 
Unknown cause 106 1.27 0.96 - 1.67 
 
130 0.90 0.68 - 1.18 0.081 
External causes 176 1.03 0.83 - 1.29 
 
93 1.25 0.93 - 1.69 0.313 
 
1 P for different association between rs1051730 and mortality depending on age category.   
Supplementary Figure S2: Associations between number of smoking increasing alleles of rs1071530 and mortality, results from a random effect 
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Supplementary Figure S3: Hazard ratios for mortality from infectious and parasitic diseases per effect allele of rs1051730 according to smoking 
status. Meta-analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
  
Abbreviations: y=years  
Supplementary Figure S4: Hazard ratios for mortality from neoplasms per effect allele of rs1051730 according to smoking status. Meta-analysis of 
the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
Abbreviations: y=years  
Supplementary Figure S5: Hazard ratios for mortality from endocrine and metabolic diseases per effect allele of rs1051730 according to smoking 
status. Meta-analysis of the HUNT2 Study (1995-97), and the UK Biobank (2006-2010). 
  
Abbreviations: y=years   
Supplementary Figure S6: Hazard ratios for mortality from mental and behavioural disorders per effect allele of rs1051730 according to smoking 
status. Meta-analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
  
Abbreviations: y=years   
Supplementary Figure S7: Hazard ratios mortality from diseases of the nervous system and sense organs per effect allele of rs1051730 according 
to smoking status. Meta-analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
 Abbreviations: y=years   
Supplementary Figure S8: Hazard ratios for mortality from circulatory diseases per effect allele of rs1051730 according to smoking status. Meta-
analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
Abbreviations: y=years  
Supplementary Figure S9: Hazard ratios for mortality from respiratory diseases per effect allele of rs1051730 according to smoking status. Meta-
analysis of HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
  
Abbreviations: y=years  
Supplementary Figure S10: Hazard ratios for mortality from diseases of the digestive system per effect allele of rs1051730 according to smoking 
status. Meta-analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
Abbreviations: y=years  
Supplementary Figure S11: Hazard ratios for mortality from diseases of the musculoskeletal system and connective tissue per effect allele of 
rs1051730 according to smoking status. Meta-analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
Abbreviations: y=years  
Supplementary Figure S12: Hazard ratios for mortality from genitourinary diseases per effect allele of rs1051730 according to smoking status. 
Meta-analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
Abbreviations: y=years  
Supplementary Figure S13: Hazard ratios for mortality from ill-defined causes per effect allele of rs1051730 according to smoking status. Meta-
analysis of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
  
Abbreviations: y=years  
Supplementary Figure S14: Hazard ratios for mortality external causes per effect allele of rs1051730 according to smoking status. Meta-analysis 
of the HUNT2 Study (1995-97) and the UK Biobank (2006-2010). 
 
Abbreviations: y=years  
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